Department of Surgery, Medical University of Vienna, Vienna, Austria.
Breast Cancer Res. 2010;12(6):216. doi: 10.1186/bcr2768. Epub 2010 Dec 17.
Treatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for these women. Several recent studies demonstrated that the anticancer activity of bisphosphonates is not limited to bone, and can translate into a reduction in disease recurrence, including reductions in locoregional and distant metastases. In addition, bisphosphonates maintain bone health during adjuvant therapy; this may be especially important for women who are at high risk for fracture.
早期乳腺癌女性的治疗选择从未如此之好，并且将双膦酸盐加入辅助治疗是一种非常有价值的新工具，能够极大地改善这些女性的临床结局。最近的几项研究表明，双膦酸盐的抗癌活性不仅局限于骨骼，还可以转化为降低疾病复发率，包括减少局部和远处转移。此外，双膦酸盐在辅助治疗期间保持骨骼健康；对于骨折风险高的女性来说，这可能尤为重要。
